Effects of niravoline (RU 51599), a selective kappa-opioid receptor agonist on intracranial pressure in gradually expanding extradural mass lesion

Journal of Neurotrauma

Volumn 15, Issue 2, 1998, Pages 117-124

  Bemana, Iraj ^a   Nagao, Seigo ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Brain edema; Cat; Cerebral prefusion pressure; Extradural balloon compression; Intracranial pressure; Kappa opioid receptor; Niravoline (RU 51599)

Indexed keywords

ELECTROLYTE; KAPPA OPIATE RECEPTOR AGONIST; NIRAVOLINE; RINGER LACTATE SOLUTION; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GAS; BRAIN PERFUSION; BRAIN WATER; CAT; COMPRESSION; CONTROLLED STUDY; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OSMOLALITY; PERFUSION PRESSURE; PUPIL;

EID: 0031886540     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/neu.1998.15.117     Document Type: Article

References (12)

1. ASHTON, N., BALMENT, R.J., and BLACKBURN, T.P. (1990). κ-opioid receptor agonists modulate the renal excretion of water and electrolytes in anaesthetized rats. Br. J. Pharmacol. 99, 181-185.
2. BELLISSANT, E., DENOLLE, T., SINNASSAMY, P., BICHET, D.G. et al. (1996). Systemic and regional hemodynamic and biological effects of a new κ-opioid agonist, niravoline, in healthy volunteers. J. Pharmacol. Exp. Ther. 278, 232-242.
3. BOSCH-MARCE, M., JIMENEZ, W., ANGELI, P. et al. (1995). Aquarelle effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 109, 217-223.
4. BROOKS, D.P., GIARDINA, G., GELLAI, M. et al. (1993). Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. J. Pharmacol. Exp. Ther. 226, 164-171.
5. BULLOCK, R., SMITH, R., FAVIER, J., TREVOU, M.D. and BLAKE, G. (1985). Brain specific gravity and CT scan density measurement after human head injury. J. Neurosurg. 63, 64-68.
6. DEBODO, R.C. (1944). The antidiuretic action of morphine and its mechanism. J. Pharmacol. Exp. Ther. 82, 74-85.
7. GUENIAU, C., BERTELEAU, L., and OBERLANDER, C. (1995). Protection from ischemic focal cerebral oedema in mice by two kappa opioid receptor agonists, Niravoline and U 50488. J. Cereb. Blood Flow Metab. 15, Suppl. (1), S383.
8. HAMON, G., CLEMENCE, F., FORTIN, M. et al. (1994a). Niravoline hydrochloride, a novel selective kappa agonist with marked aquaretic properties but low analgesic potency (abstr.). Brit. J. Pharmacol. 114 (suppl.), 310P.
9. HAMON, G., FORTIN, M., LE MARTRET, O., JOUQUEY, S., VINCENT, J.C., and BICHET, D.G. (1994b). Pharmacological profile of niravoline, a new aquaretic compound (abstr.). J. Am. Soc. Nephrol. 5, 272.
10. HERKENHAM, M., RICE, K.C., JACOBSON, A.E., and ROTHMAN, R.B. (1986). Opiate receptors in rat pituitary are confined to the neural lobe and are exclusively kappa. Brain Res. 382, 365-371.
11. HUIDOBRO, F. (1978). Antidiuretic effect of morphine in the rat: Tolerance and physical dependence. Br. J. Pharmacol. 64, 167-171.
12. LEANDER, J.D., ZERBE, R.L., and HART, J.C. (1985). Diuresis and suppression of vasopressin by kappa opioids: Comparison with mu and delta opioids and clonidine. J. Pharmacol. Exp. Ther. 234, 463-469.